Polymerase chain reaction (PCR) technology was employed to examine peripheral blood and synovial T cells in patients with rheumatoid arthritis (RA) for biased utilization of T cell receptor (TCR) variable region (V) genes. Oligonucleotide primers specific for individual TCR V beta gene families were used to amplify TCR gene products in a semiquantitative assay of their relative utilization in unselected T cell populations. Mean V beta expression in 24 RA peripheral blood samples was very similar to that in a panel of 15 normal subjects, except for a slight decrease in V beta 13.2 expression. V beta utilization in 8 RA synovial tissue samples and 13 synovial fluid samples was compared to simultaneously obtained blood samples. Although heterogeneous patterns of skewed V beta utilization were observed, several significant trends emerged. By a number of approaches to data analysis, a statistically significant increase in expression of V beta 6 and V beta 15 in synovial T cells was documented. In addition, increased synovial expression of V beta 14 was found, but only in the synovial fluid samples. Reduced expression of V beta 1, V beta 4, V beta 5.1, V beta 10, V beta 16, and V beta 19 was also observed in synovial T cells. (J. Clin. Invest. 1993. 92:2688-2701
Introduction
Rheumatoid arthritis (RA) is an idiopathic disease characterized by chronic inflammation of synovium, local destruction of cartilage and bone, and systemic illness. Several lines of evidence implicate T cells which respond to antigenic stimuli via their a /f T cell receptor (TCR)' in the disease process ( 1 ) . The majority of RA patients express products of a set of alleles 1 . Abbreviations used in this paper: C or V, constant or variable region (gene); DMARD, disease-modifying antirheumatic drug; NSAID, nonsteroidal antiinflammatory drug; RF, rheumatoid factor; RT, reverse transcriptase.
at the B 1 locus of the HLA-DR region, HLA-DRB 1 *0401 (HLA-DR4, Dw4), *0404/*0408 (DR4, Dw14), *0405 (DR4, Dwl5), *0101 (HLA-DR1), and *1402(HLA-DRwl4, Dw 16) , that are associated with increased risk for acquiring the disease (2-7). These class II MHC molecules share a sequence of amino acids in the third hypervariable region (residues 70-74) of the HLA-DRfl chain, indicating that this epitope may confer disease susceptibility (8) . Because the major roles of class II molecules are to bind and present antigenic peptides to CD4+ T cells or to exert an influence on thymic selection ofthe CD4+ T cell repertoire, these findings are compatible with the conclusion that the introduction of an unidentified pathogenic antigen into the synovial membrane of an immunogenetically susceptible host triggers a CD4+ T cell-mediated autoimmune response resulting in the manifestations of RA.
A number of studies have established the ability of antigen or autoantigen plus MHC combinations to select for T cells expressing particular TCR genes (9) . There is also evidence that the variable region (V) gene expression profile of peripheral T cells can be influenced by the MHC molecules encountered during thymic education (10) (11) (12) (13) . In addition, it has been postulated that superantigens, characterized in part by their ability to stimulate T cells utilizing particular V/I genes, may play a role in the development ofautoimmunity including RA (14, 15) . Thus, there are several factors that could lead to the development of biased TCR expression in RA.
Initial studies sought evidence ofbiased TCR expression in RA by looking for the presence ofoligoclonal T cells. Evidence of oligoclonality manifested by the presence of rearranged bands detected by Southern blotting was rarely found in T cells directly isolated from synovial fluid samples (16, 17) . Moreover, T cell clones established in culture conditions designed to allow outgrowth ofall cells rarely exhibited identical rearrangements (18, 19) . However, some studies were able to detect oligoclonality ofsynovial T cells selected for the ability to grow in IL-2 alone (20, 21) . Even when oligoclonality was claimed, however, there was no consensus on the specific dominant rearrangement in different patient samples (22, 23) . Taken together, these studies indicate that there is minimal oligoclonality in the rheumatoid synovium, although selection for IL-2-responsive T cells may induce outgrowth of a limited number ofclones. A major limitation ofthese analyses, however, is that examination of cells for identical rearrangement patterns might not detect the predominance ofan antigen-or superantigen-reactive T cell population utilizing particular Va (24) , whereas others have reported that, at least in patients with early disease, a limited number of Va, but not V/I, gene families are expressed (25) . Although variable numbers of Va and VB products were also detected in other studies ofsynovial fluid or synovial tissue samples ( 14, 26) , two recent analyses of synovial fluid T cells detected all of the V: families in every patient (27, 28) . Thus, no consensus concerning the potential biased expression of V: or Va in RA synovium has emerged from these studies, most of which examined small numbers of patients. Some studies included comparisons of V gene expression in rheumatoid peripheral blood and synovial T cells. Analyses of increased synovial T cell expression of individual V gene families have generally demonstrated heterogeneous patterns (27) (28) (29) (30) . However, Paliard et al. ( 14) reported that, in nine of nine RA patients, expression of Vl14 was greater in synovial fluid T cells than in the peripheral blood. An increase in Vf14 expression in synovial fluid T cells in comparison to peripheral blood was found in one other study (29) , but not in two others (27, 28) . Therefore, the question ofwhether there is biased representation or activation ofT cells expressing particular Va (33, 34) . DNA was extracted from lymphocytes as described (35) , and amplified by PCR using previously described primers for DR(3 (33) , DQB (36) , DP# (36) , and DR4 subtyping. Previously described oligonucleotides were used for probing dot blots of the DRf3 (33) , DP# (36) , DQB (34) , and DR4 (36) PCR products.
Cellpreparationfor TCR analysis. PBMC and synovial fluid mononuclear cells were prepared from heparinized samples by density gradient centrifugation over ficoll diatrizoate gradients. These cells were either used directly for RNA preparation or further enriched for T cells by rosetting with neuraminidase-treated sheep erythrocytes and/or passage over a nylon wool column. Lymphocytes were prepared as described (37) (Table I) and from all of the control subjects a negative control cDNA, prepared from RNA without added RT, was tested with Cfl region primers to ensure there was no contaminating TCR DNA. Products were sampled after 20, 25, 30, and 35 cycles to determine the number of cycles through which the specific product accumulated exponentially (see Fig. 1 A) . The subsequent semiquantitative assay utilized the 22 VB family-specific 5' primers designed by Choi et al. (40) and the reverse primer 3'CB4: ACCCACCAGCTCAGCTCCA in separate simultaneous PCR reactions. The number of cycles used (usually 22-30) was designed to stop the reactions while all of the products were still accumulating exponentially, as determined in the preliminary experiment. These steps were taken to ensure that each PCR product was proportional to the amount ofcorresponding mRNA. In addition, when possible, all of the reagents were aliquoted from a master mix so that pipetting variability did not produce artifacts in the PCR. In each experiment a negative control, with no cDNA added, was run in parallel for all primer pairs. PCR amplification of cDNA samples from subjects RA-1, RA-2, CP-4, and one of the sets of synovial fluid and peripheral blood samples from RA-3 was performed in individual tubes in a reaction volume of 50 ,l. Amplification ofsamples from RA-7, NC-I 1, and one of two sets of synovial fluid mononuclear cell and PBMC samples from RA quently, differences in an individual Vf3/Cf3 ratio from one cDNA to another might reflect this inconsistency rather than true skewing. In contrast, when the data were normalized with the sum of the 22 VJ3 amplifications repeat experiments performed on the same cDNA produced nearly identical V/3 expression profiles (see Results). This consistency allowed meaningful comparisons of different cDNAs. The ability of this semiquantitative assay to detect selective expansion or activation of T cells bearing a particular Vf3 gene was demonstrated in preliminary experiments and in experiments published elsewhere. Peripheral T cells stimulated with monoclonal antibodies directed against specific V,3 proteins in the presence of IL-2 produced at least a twofold increase in the amount of the appropriate V# PCR product even though there was no detectable increase in the number of cells in culture (data not shown), demonstrating that increased amounts of mRNA resulting from activation of VA3-specific T cells could be detected. In addition, proliferation driven by Vf3-specific superantigens resulted in a marked increase of the appropriate V13 PCR product (41 ) . Finally, addition of small numbers of monoclonal T cell populations (5%) to T cells derived from the peripheral blood of a normal donor was easily detected (data not shown). These preliminary results confirmed that the semiquantitative PCR could detect changes in both the activation state and number of T cells expressing specific VB gene products in a heterogeneous population. Statistical analysis. Vf3 expression in the peripheral blood and synovium of RA patients and in the peripheral blood of control subjects was not normally distributed for every Vj3 gene family. Therefore, Wilcoxon's rank sum test was applied to comparisons of Vfl expression in RA patients and control groups, and Wilcoxon's signed rank test was applied to comparisons of Vj3 expression in simultaneously obtained peripheral blood and synovial samples. Student's t test was applied to comparisons of V: expression in peripheral blood and synovium in each experiment performed with triplicate PCR amplifications. Regression analysis was used to examine the overall similarity of V3 expression profiles in different experiments. The coefficient ofdetermination (r2) is reported, with r2 = 1.0 indicating perfect correlation, and r2 = 0 indicating no correlation.
Results
Patient population. Samples were obtained from 24 RA patients, 4 patients with other arthritides, and 15 normal donors. The clinical characteristics of these subjects are presented in Table I . A large majority ofthe RA patients had erosive synovitis and all ofthem were functional class II or III (42) . Rheumatoid factor (RF) was detected in the serum of20 RA patients. A majority ( 15/24) of the RA patients was taking a disease-modifying antirheumatic drug (DMARD) at the time the samples were obtained. Ofthe 23 patients on whom serologic HLA-typing was available, 12 expressed either HLA-DR 1 or HLA-DR4 or both. 5 ofthe 15 normal subjects tested positive for either or both ofthese markers. Of the 8 HLA-DR4+ patients who were DNA typed, 7 expressed at least one of the susceptibility conferring alleles DRB 1 *0401, *0404, or *0408. For clarity of presentation, serologic typing ofHLA-A, B, and C, and DNA analysis of DP, DQ, and DR4 subtypes, are not shown.
RA peripheral blood. Fig. 1 illustrates the protocol used in these experiments for the analysis of Vfl gene family expression in unselected T cell populations. The preliminary analysis of the peripheral blood cDNA of one subject indicated that TCR CJ3 product accumulated exponentially for 30 PCR cycles ( VB gene family specific 5' primers. The hybridized slot blots of this experiment are shown in Fig. 1 , B and C. Quantifying of the net hybridized counts, depicted in Fig. 1 D, indicated a low degree of well-to-well variability in the triplicate PCR amplifications. The normalized data from this experiment are depicted in Fig. 2 . Each cDNA in this report was subjected to a similar analysis. Circulating T cells from the blood of 24 RA patients with active disease were examined for biased TCR expression in comparison with TCR expression in the peripheral blood of 15 normal donors. Although two blood samples were available from 2 RA subjects, only one sample from each was used in this analysis. Restricted VB gene family utilization was not observed in RA patients nor in normal donors. For example, all of the 22 Vfl products were detected at levels exceeding 1% of the total in the blood of patient RA-23 ( Fig. 1 C, and Fig. 2 ). At least 16 of the 22 VB products represented 1% or more of the total in every blood sample; the mean for all ofthe blood samples was 20 V3 products > 1% (data not shown). Every Vp family comprised 1% or more of the total in the peripheral blood of 90% or more of the subjects tested, except for V3 IO and V#l 1 which were expressed to this level in 56% and 51%, respectively. The patterns of TCR expression were heterogeneous in both RA patients and controls. The data summarized in Table II expression was also significantly lower in the patients than in the controls. In addition, RA patients in this group expressed significantly higher levels of V,32 and Vf35. 1 than did this normal donor group.
The potential effect of disease duration was explored by comparing peripheral blood Vf3 expression in subjects having RA for 2 yr or less, and those having RA for more than 2 yr, to each other and to the normal subjects. There were no statistically significant differences between the group of 16 RA patients with longer disease duration and normal donors, nor between this group of patients and the group of 8 with shorter disease duration. However, VB 1 3.2 expression (3.0±0.5%) was lower in the patients with RA for 2 yr or less than in the normal donors (Table II) (P < 0.004), whereas V,320 expression (4.1±0.5%) was higher in this group of RA patients (P < 0.039).
Similarly, the possibility that peripheral blood Vf expression differed in patients taking nonsteroidal antiinflammatory drugs (NSAIDs) alone and patients taking DMARDs was ex- has the potential advantage of revealing significant trends apparent in the entire group that could have been of modest magnitude in individual cases. On the other hand, if there was marked heterogeneity within the group, biologically meaningful differences in individual cases might be obscured. Tabulation of the number of individual comparisons in which a bias was either statistically significant or exceeded 50% was performed to address this possibility. In order to examine the possibility that biased V: utilization may be limited to certain subsets of RA patients, these analyses were performed on: (a) the entire set of samples; (b) those in which either synovial tissue or synovial fluid was analyzed; (c) samples from RF+ patients; (d) samples from subjects known to express HLA-DR1 or DR4; (e) samples from patients with RA for 2 yr or less, or for more than 2 yr; (f) samples from patients taking DMARDs; and (g) samples from patients taking NSAIDs alone.
The Vf expression of T cells in synovial tissue at the time of joint replacement or synovectomy was determined in eight RA patients, six of whom were seropositive for RF. Histologic examination was performed on four of these synovial specimens and confirmed the presence of an active inflammatory infiltrate in each case. Vfl expression in simultaneously obtained peripheral blood T cells was used for comparison. An example of this type of experiment is shown in Fig. 2 Synovial fluid samples obtained at the time of therapeutic arthrocentesis were also examined and compared to simultaneously obtained peripheral blood T cells in 13 RA cases (synovial fluid and blood were obtained from two patients on two occasions). 12 of the samples were obtained from RF+ patients. This analysis (TableIII) revealed that V/i6.1-3 and Vl 14 expression in the 13 synovial fluid T cell samples was significantly higher than that in the peripheral blood. On the other hand, synovial fluid expression of Vf4, V,1 6, and V#ll 9 was significantly lower than in the peripheral blood samples. In addition, mean expression of VB 4, Vl 6, and V/31 9 in RA synovial fluid was significantly lower than in normal donor peripheral blood (P < 0.0 14).
As was the case with peripheral blood, restricted Vl# gene (Table III) . Moreover, in the synovium of this group of patients the mean V#31 5 expression was significantly higher (P < 0.01), and the mean Vf4 and V,3I0 expression was significantly lower (P < 0.0 14), than that in the peripheral blood of normal donors known to express these HLA antigens.
Individual analysis of rheumatoid synovium and peripheral blood in the (a) 9 samples from patients with RA for 2 yr or less; (b) 12 Synovial fluid and peripheral blood samples were obtained on two occasions 9 mo apart from subject RA-11. These two comparisons of synovial fluid and peripheral blood are depicted in Fig. 3 . At both time points it is clear that T cell V,3 expression is not identical in the synovial fluid and peripheral blood. Regression analysis was used to determine the degree of overall similarity of V,3 expression. The coefficient of determination (r2) for peripheral blood and synovial T cell V,3 expression was 0.78 at the first time point and 0.84 at the second time point. This degree of similarity was relatively high in comparison to that observed in similar experiments; the mean r2 for the 21 comparisons was 0.57 with 95% confidence intervals of 0.47-0.67. It is also evident from These results indicate that differences observed in comparisons of different cDNAs are unlikely to be artifactual. Expression of 10 V3 families differed by 50% or more in the first comparison of peripheral blood and synovial fluid T cells in RA-1 1, whereas 7 V: families differed to this degree in the second comparison (Fig. 3) . Decreased synovial T cell expression of Vf34 and Vf3 19 was seen on both occasions, consistent with the overall similarity of both peripheral blood and synovial fluid Vf3 expression at the two timepoints. Samples were also obtained from subject RA-3 on two occasions 3 mo apart (data not shown). A summary of the 13 synovial fluid analyses is presented in Table IV . Heterogeneous skewing continued to be noted as there are at least two examples of biased expression for each VA gene family. Similar to the synovial tissue comparisons, increased synovial fluid expression of V3 15 and greater peripheral blood expression of V34, Vf5. 1, VBI0, and V# 1 6 was frequently observed. In addition, there were several cases where synovial fluid expression of Vf 1 and V3 19 was substantially less than that in the peripheral blood. There were only two cases in whom peripheral blood expression of VB14 was 50% less than in the synovial fluid. Only one of the six RF+, HLA-DR 1 or DR4 patients exhibited a 50% or greater decrease in peripheral blood expression of V,14 in comparison to synovial fluid. Nevertheless, peripheral blood expression of VB14 was modestly but significantly lower than that of synovial fluid in this group of six patients (2.5% vs. 3.4%, P = 0.031 ), as it was for the entire group of synovial fluid samples (Table III) .
Taking the synovial tissue and synovial fluid samples together synovial and peripheral blood TCR Vp expression was compared in 21 cases, 18 of which were from seropositive patients. Increased expression of V,15, V36. 1-3, Vf2, V3 12, and VB13.1 was observed most frequently in synovial T cells, whereas increased expression of VB4, VB5.1, VB10, V#l9, V# 1 6 and V#3I was seen more frequently in peripheral blood (Table IV) . When the samples were analyzed for larger differences between synovial and peripheral blood expression ofindividual V3 gene families, biases continued to be noted. Thus, when twofold or greater differences were required, 9 of 18 RF+ patients exhibited increases in peripheral blood expression of V,34 (no cases of opposite bias), whereas 8 RF+ patients manifested greater expression of V# 15 in synovial T cells (one case of opposite bias).
A comparison of synovial and peripheral blood T cell utilization of Vg families was performed in eight seropositive RA patients who expressed HLA-DRl or HLA-DR4 (Table IV) . Synovial T cell expression of Vfl15 was at least 50% greater than peripheral blood in five of these patients, whereas increased peripheral blood expression ofV: 1, Vf34, Vf35. 1, V 10, and Vj 16 was seen in five, six, eight, six, and four cases, respectively. In total, 19 comparisons ofsynovial and peripheral blood T cells were done using triplicate amplifications of cDNA with each primer pair. Statistical analysis could therefore be directly applied to these comparisons. Examination of the data in this way has the advantage of detecting biased V: gene expression that may be statistically significant but not of sufficient magnitude to meet the 50% cutoff used in the analyses presented above. For example, in the comparison shown in Fig. 2 , synovial tissue T cell and peripheral blood T cell expression of VfB2, Vfl5.1, V,36.1-3, V,132, Vf313.1, and V 16 were significantly different (P < 0.05). The difference in V#2 expression, however, was < 50%. Similarly, in both of the experiments shown in Fig. 3 there were three examples of significant bias in which the magnitude of the difference was < 50%. Table V (Table V) . Of note, V/6. 1-3 was significantly overexpressed in 10 of 19 synovia (Table V) , although this overexpression was > 50% in only 6 of 21 cases (Table IV) . Similarly, there were only 2 of 13 cases where V/14 expression was 50% less in peripheral blood than synovial fluid (Table IV) , but of the 12 synovial fluid comparisons done in triplicate, 4 exhibited a statistically significant decrease in peripheral blood V/i14 expression (data not shown).
Discussion
The TCR repertoire of peripheral T cells is determined in part by the genetic elements which encode the TCR, by self-MHC antigen-directed positive and negative selection during thymic education, and presumably by the antigens or superantigens the individual has encountered. As RA is a chronic inflammatory disease with a genetic susceptibility linked to MHC class II genes, any or all of these determinants could produce a bias in the peripheral blood or synovial TCR repertoire. The present study provides the strongest evidence to date that biased V/ gene utilization can be observed in unselected T cell populations from RA patients.
There was substantial subject-to-subject variability in pe- expressing either of these markers. This analysis revealed several significant differences between these groups. V/Il 3.2 and V/8 expression was lower in the patients than in the controls, whereas V/2 and V/i5. 1 expression was higher. The observation that a greater degree ofbias was evident in a comparison in which the two groups shared some MHC alleles suggests that events related to the disease process itself, such as antigen or superantigen stimulation, alter the expression ofTCR V/ products in the peripheral blood of RA patients.
Paliard et al. ( 14) observed that the expression of V/I 14 in the peripheral blood of six of nine RA patients was undetectable or substantially diminished in comparison to peripheral blood of normal donors and arthritic controls. In the current study, the V/ 14 PCR product was detectable in every RA patient and normal donor examined, representing 0.9% or more of the total. The mean expression in RA patients was lower than that in the control group (2.7% vs 3.4%), but the differ-ence did not achieve statistical significance (P = 0.07). In the current group of RA patients known to express HLA-DR1 or DR4 (as did all of those studied by Paliard et al.) the mean peripheral blood expression of V 14 was lower than that ofthe control donors who expressed these HLA antigens (Table III) , but again the difference was not statistically significant (P = 0. 16). Differences in the study populations may explain the somewhat disparate results obtained in these two studies. In addition, there were a number of methodological differences that might have influenced the results, including stimulation of the cells prior to RNA preparation in the aforementioned study as well as major differences in the PCR technique, means of normalization of the data, and data analysis. In preliminary experiments we have attempted to determine the impact of these variables on the data generated in each study, but have been unable to document that these methodological differences explain the disparate results. Thus, for example, we found that inclusion of an additional pair of oligonucleotides (such as Ca primers) to provide an internal amplification control did not enhance the reproducibility of the V# amplifications. In addition, although we found that expression ofa number of the V3 families was significantly altered by stimulation of the cells with anti-CD3 antibodies and IL-2 before analysis, this did not decrease expression of Vf14 by blood T cells. Since most of the data was generated from triplicate PCR amplifications and the standard error of the mean was quite small, the current data persuasively argue that V 14 is not substantially decreased in the blood of patients with RA. One other study of 3 RA patients and 2 normal donors came to a similar conclusion (27) .
A number of previous studies have analyzed TCR V gene expression in RA using a variety of techniques, but did not produce a clear picture of the degree of restricted V gene expression in RA synovium or peripheral blood (Table VI) . Studies examining RA peripheral blood and synovium for biased V gene expression have also not produced consistent results, perhaps because many of these examined only small numbers of patients. Two studies described greater synovial fluid expression of V 14 (14, 29). In the current study Vf314 expression in synovial fluid was significantly greater than in the simultaneously obtained peripheral blood samples. This bias is consistent with the results of Paliard et al. ( 14) . However, the magnitude of the difference was much less marked in the current study than in the prior study and was not observed in synovial tissue. It is noteworthy that V#314 expression has been observed to be enriched in CD8+ T cells (43) (44) (45) which are usually increased in RA synovial fluid (46) (47) (48) . Thus, it is possible that differences in Vf3 14 expression are at least partially related to alterations in the proportion ofCD8+ cells found in peripheral blood and synovial fluid.
Immune responses to local introduction of an antigen result in infiltration by antigen-specific T cells and by large numbers of nonspecific T cells. Thus, one can assume that T cells responding to pathogenic peptides in rheumatoid synovium represent a small minority of infiltrating T cells. The large proportion ofnonspecific T cells may produce variability in the V: expression profile of T cell populations with time as was noted in the samples obtained from the same patient at two points in time. These considerations may also partly explain the difference between the present study and those of others. Examination of a large number of patients with a semiquantitative approach comparing synovial and peripheral blood T cell Vf expression in this study allowed the identification of biased TCR expression despite the presence of nonspecific T cells expressing other TCR Vf3 gene products. Many of the previous reports studied an insufficient number of patients for consistent biases to emerge, or did not perform comparisons to peripheral blood rendering conclusions regarding TCR bias somewhat speculative. Moreover, the current study was designed to provide an accurate determination of V: expression by T cells as they are found in situ within the synovium or peripheral blood of RA patients. Therefore, stimulation of the cells prior to analysis, as was done in other studies, was avoided. Moreover, since there is no conclusive evidence that one or another ofthe specific T cell subsets present in the synovium is responsible for disease pathogenesis, no effort was made to isolate indi- (Table V) , although the magnitude of increased expression was sometimes less than 50%. The expression of Vf15 in the synovial tissue samples, in the group of 21 synovial samples, and in the group of synovial samples from HLA-DR1/DR4+ patients was significantly greater than that in the simultaneously obtained peripheral blood samples (Table III) . The bias toward synovial T cell expression of Vf 15 was also apparent in synovial fluid samples in which 6 of 13 cases exhibited at least a 50% greater expression of V3 15 (Table IV) . Thus, increased Vf6.1-3 and increased V3 15 expression in rheumatoid synovium were established by a number of analytic methods.
Evidence of biased V: expression in rheumatoid synovium was also revealed by decreased expression of certain VI3 families. Vfl1, VB4, VB5.1, VflI0, VB16, and Vf l9 expression by synovial T cells was significantly lower than in the corresponding blood samples. It has been reported that V35. 1 expression was skewed toward the CD4+ subset (43, 45, 49) . This subset bias may contribute to the relative decrease in VB5. 1 expression in synovial fluid, but is probably less ofa factor in synovial tissue where the relative proportion of CD4 and CD8 single positive cells is usually the same as in peripheral blood (37, 50 (Tables III and IV) . However, greater numbers ofseronegative RA patients, and longitudinal study of several patients, would be required to determine definitively the impact of RF, disease duration, or medications on V: expression by synovial T cells. The high level of expression of the V36 family in the synovial and peripheral blood T cells of RA patients, and in the peripheral blood ofthe control subjects is likely to be related to the size of the V,36 family which contains at least nine members. However it is evident from the data in Tables II and  III that 
